



(51) International Patent Classification:

A61K 39/00 (2006.01) C12N 15/62 (2006.01)
A61K 35/17 (2025.01) C07K 14/70 (2006.01)
C07K 14/495 (2006.01) C07K 14/71 (2006.01)

(21) International Application Number:

PCT/US2024/019778

(22) International Filing Date:

13 March 2024 (13.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/489,979 13 March 2023 (13.03.2023) US

(71) Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; 3600 Civic Center Boulevard, 9th Floor, Philadelphia, Pennsylvania 19104 (US).

(72) Inventors: O'ROURKE, Donald; 24 Greenhill Lane, Wynnewood, Pennsylvania 19096 (US). BINDER, Zev; 349 Calvert Road, Merion Station, Pennsylvania 19066 (US).

(US). RODRIGUEZ, Jesse; 5 Chestnut Avenue, Wilmington, Delaware 19805 (US). LI, Nannan; 4311 Baltimore Avenue, Philadelphia, Pennsylvania 19104 (US).

(74) Agent: PFANNENSTIEL, Lukas W. et al.; Saul Ewing Arnstein & Lehr LLP, Centre Square West, 1500 Market Street, 38th Floor, Philadelphia, Pennsylvania 19102 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: GENERATION OF CAR MODIFIERS FOR TUMOR TREATMENT




FIG. 1

(57) Abstract: The present disclosure provides modified immune cells or precursors thereof (e.g. T cells) comprising a first chimeric antigen receptor (CAR) capable of binding human IL13Rα2, a second CAR capable of binding EGFR or an isoform thereof, and a dominant negative TGFβ type II receptor (DN-TGFβRII). Compositions and methods of treatment are also provided.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
26 December 2024 (26.12.2024)